Genmab has signed a global licence and option agreement with Janssen Biotech for the development and commercialisation of a human CD38 monoclonal antibody (mAb).

Called HexaBody-CD38, the mAb will incorporate Genmab’s proprietary HexaBody technology, which creates effector function enhanced antibodies. The companies are aiming to expand the potential of CD38-targeted therapies to additional indications.

Genmab will sponsor research and development (R&D) activities of the therapeutic until completion of clinical proof-of-concept studies in patients with multiple myeloma and diffuse large B-cell lymphoma.

Based on the results of these studies, Janssen may exercise its option for a worldwide licence to develop, manufacture and commercialise the mAb. If used, Genmab will receive a $150m option exercise fee and up to $125m in development milestones.

Janssen will also pay a 20% royalty on sales of HexaBody-CD38 until 2031, followed by 13%-20% tiered royalties thereafter.

If the company decides not to exercise its option, Genmab will continue the development and commercialisation of the product for Darzalex-resistant patients and additional indications. However, the agreement excludes multiple myeloma or amyloidosis indications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Genmab CEO Jan van de Winkel said: “With this agreement, we hope to build upon the successful and productive relationship that we have established with Janssen. As a result of our collaboration, Darzalex has dramatically improved outcomes for patients with multiple myeloma, yet there are still unmet needs for patients.

“Encouraging pre-clinical data suggest that HexaBody-CD38 could be superior to daratumumab for certain tumour cell types and may expand and extend the promise of CD38-targeted therapies for more patients with multiple myeloma, lymphoma, leukaemia, and potentially beyond.”

HexaBody-CD38 yielded promising data in multiple myeloma, lymphoma and leukaemia models.

Genmab and Janssen previously partnered to develop Darzalex (daratumumab), a CD38-targeting anti-cancer drug intended to treat amyloidosis, multiple myeloma and blood cancers.